Wave Life Sciences, Inc.
WVE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001631574
In the last 90 days, Wave Life Sciences, Inc. insiders filed 0 open-market purchases and 4 sales; 239 institutions reported holding it in 13F filings for Q2 2026, worth $1.06B in total; superinvestors Maverick Capital and Duquesne Family Office hold it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $135.1K in total
- 4
- 13F holdersQ2 2026, +11 vs. previous quarter
- 239
- 13F valueReported value at the end of Q2 2026
- $1.06B
- Superinvestors holdingAt the end of Q2 2026
- 2
Price chart
Superinvestors holding WVE, Q2 2026
2 superinvestors report holding Wave Life Sciences, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Maverick Capital
Lee Ainslie
0.5%
Wave Life Sciences, Inc.'s share of the portfolio
- Shares
- 10,278,115
- Value
- $59.7M
Duquesne Family Office
Stanley Druckenmiller
<0.1%
Wave Life Sciences, Inc.'s share of the portfolio
- Shares
- 173,000
- Value
- $1.00M
Latest insider trades
Open-market purchases and sales by Wave Life Sciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 13, 2026 (view filing)9:00 PM ET | Aug 11 | 2 days | Wagner Heidi LDirector | SSale | −7.00K | $6.01 | −$42.1K | −13.5%44.9K after | 10b5-1 |
| Aug 13, 2026 (view filing)9:00 PM ET | Aug 12 | 1 day | Rawcliffe AdrianDirector | SSale | −12.7K | $5.29 | −$67.2K | −100.0%0 after | 10b5-1 |
| Aug 13, 2026 (view filing)9:00 PM ET | Aug 11 | 2 days | Takanashi KenDirector | SSale | −3.86K | $6.01 | −$23.2K | −16.1%20.1K after | 10b5-1 |
| Aug 13, 2026 (view filing)9:00 PM ET | Aug 11 | 2 days | Tan Aik NaDirector | SSale | −432 | $6.01 | −$2.60K | −1.7%25.0K after | 10b5-1 |
| Mar 30, 2026 (view filing)8:30 PM ET | Mar 26-30 | 4 days | RA Capital Healthcare Fund LP and 3 othersDirector, 10% Owner | PPurchase | +8.77M | $6.23 | +$54.6M | +48.2%27.0M after | 4 lots |
| Feb 27, 2026 (view filing) | Feb 26 | 1 day | Francis ChrisSee Remarks | SSale | −33.2K | $15.05 | −$499.5K | −34.9%61.9K after | 2 lots10b5-1 |
| Feb 11, 2026 (view filing) | Feb 9 | 2 days | Moran KyleChief Financial Officer | SSale | −3.59K | $13.45 | −$48.3K | −2.6%134.4K after | |
| Feb 11, 2026 (view filing) | Feb 9 | 2 days | Bolno PaulPresident and CEO | SSale | −10.5K | $13.45 | −$141.0K | −3.7%275.5K after | |
| Feb 11, 2026 (view filing) | Feb 9 | 2 days | Francis ChrisSee Remarks | SSale | −1.88K | $13.45 | −$25.3K | −3.0%61.9K after | |
| Feb 11, 2026 (view filing) | Feb 9 | 2 days | Vargeese ChandraSee Remarks | SSale | −3.23K | $13.45 | −$43.4K | −0.8%408.2K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Wave Life Sciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 26,975,505 | $156.7M | 1.36% | 00.0% | Unchanged |
| BlackRock, Inc. | 19,202,461 | $111.6M | 0.00% | +5,085,049+36.0% | Added |
| GSK plc | 18,245,691 | $106.0M | 17.60% | 00.0% | Unchanged |
| Maverick Capital LtdSuperinvestorMaverick Capital | 10,278,115 | $59.7M | 0.54% | +116,716+1.1% | Added |
| Driehaus Capital Management LLC | 5,443,143 | $31.6M | 0.18% | +12,122+0.2% | Added |
| Primecap Management Co | 5,354,622 | $31.1M | 0.02% | +521,670+10.8% | Added |
| 683 Capital Management, LLC | 4,950,000 | $28.8M | 2.64% | +50,000+1.0% | Added |
| FMR LLC | 4,922,477 | $28.6M | 0.00% | −270,284−5.2% | Reduced |
| State Street Corp | 4,839,317 | $28.1M | 0.00% | +1,165,284+31.7% | Added |
| Readystate Asset Management LP | 4,727,139 | $27.5M | 1.12% | +4,727,139 | New |